OrbiMed

OrbiMed is a preeminent global investment firm exclusively dedicated to the healthcare sector, headquartered in New York City. Established with a singular focus on healthcare, the firm employs a comprehensive investment strategy that spans the entire industry, from early-stage venture capital to growth equity, public equity, and credit investments. This broad mandate allows OrbiMed to support companies at virtually every stage of their lifecycle, fostering innovation and growth across biopharmaceuticals, medical devices, diagnostics, and digital health solutions worldwide. Their deep industry expertise and extensive network are central to their value proposition, enabling them to identify and nurture promising healthcare ventures.

The firm's investment approach is characterized by its long-term perspective and a commitment to partnering with management teams to build successful enterprises. OrbiMed's global presence, with offices in major financial and biotech hubs, facilitates a diverse portfolio that reflects the dynamic nature of the healthcare landscape. As of early 2024, OrbiMed manages approximately $18 billion in assets, underscoring its significant financial capacity and influence within the healthcare investment ecosystem. This substantial capital base allows them to deploy considerable resources into both emerging and established companies, driving significant advancements in patient care and medical technology.

OrbiMed's typical first cheque sizes are reflective of its multi-stage investment strategy and the substantial capital it manages. While they participate in seed and early-stage venture rounds, their significant private equity funds enable larger commitments. For instance, in 2022, the firm closed its OrbiMed Private Investments IX fund with $4.3 billion in capital commitments, demonstrating their capacity for substantial investments. Consequently, a typical first cheque for a private company can range widely, often starting from around $10 million for early-stage venture deals and extending up to $200 million or more for growth equity or later-stage private investments, particularly when taking a lead or significant co-lead position in a funding round. This flexibility allows them to tailor their investment to the specific needs and stage of the target company, from innovative startups to established market leaders.